Evidence map›Paper›PMID 36453650›Full record

ArticleBlood advances2023

Elevated RIPK3 correlates with disease burden in myelofibrosis.

Veronika Dill, Celina V Wagner, Eva C Keller, Francisco Jose Fernandez-Hernandez, Khalid Shoumariyeh, Timo O Odinius, Lars Buschhorn, Richard T Hauch, Christian Suren, Judith S Hecker and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Veronika DillDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0002-4258-4986
Celina V WagnerDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0002-8312-3617
Eva C KellerDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0001-6146-9425
Francisco Jose Fernandez-HernandezClinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Khalid ShoumariyehDepartment of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Timo O OdiniusDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0002-9722-4582
Lars BuschhornNational Center for Tumor Diseases, Heidelberg, Germany.
Richard T HauchPediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-1282-4803
Christian SurenDepartment of Orthopedics and Sports Orthopedics, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Judith S HeckerDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0002-1531-0517
Peter HerhausDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Michael SandherrGemeinschaftspraxis Hämato-Onkologie Weilheim, Weilheim, Germany.
Burkhard SchmidtGemeinschaftspraxis Hämato-Onkologie Pasing, Munich, Germany.
Julia Slotta-HuspeninaInstitute of Pathology, Technical University of Munich, Munich, Germany.
Florian BassermannDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Ulrike HöckendorfDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Stefanie JilgGemeinschaftspraxis Onkologie Erding, Erding, Germany.
Caterina BrancaDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Sebastian VosbergClinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Philipp J JostDepartment of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
TUM Klinikum · DEGerman Cancer Research Center · DEMedical University of Graz · ATPraxis für Hämatologie und Onkologie · DENational Center for Tumor Diseases · DETechnical University of Munich · DEUniversität Hamburg · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Primary MyelofibrosisCost of IllnessHumansReceptor-Interacting Protein Serine-Threonine KinasesReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, human

Identifiers

PMID36453650
PMCPMC10111350
OpenAlexW4310572723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.